Compare AIHS & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIHS | EDSA |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 7.5M |
| IPO Year | 2017 | 2018 |
| Metric | AIHS | EDSA |
|---|---|---|
| Price | $1.75 | $6.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 23.0K | ★ 7.4M |
| Earning Date | 02-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.63 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,389,072.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.25 | $0.72 |
| 52 Week High | $8.26 | $9.37 |
| Indicator | AIHS | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 72.72 | 59.46 |
| Support Level | $1.84 | $1.69 |
| Resistance Level | $3.07 | $8.74 |
| Average True Range (ATR) | 0.17 | 1.48 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 67.55 | 49.31 |
Senmiao Technology Ltd is a holding company. Along with its subsidiaries, it is engaged in facilitating automobile transactions and offering related services. The group's business activities include providing car rental services to individual customers with lease term no more than twelve months; leasing and servicing of new energy vehicles; offering services to automobile purchasers throughout the purchase process; providing management and related services to Partner Platforms and other companies; automobile financing; and providing other related supporting services to customers. The majority of the group's revenue is generated from its automobile rental business.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.